Takeda Pharmaceutical (TAK) Cash from Investing Activities (QoQ) (2018 - 2026)
Takeda Pharmaceutical (TAK) Cash from Investing Activities (QoQ) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.12 Bn | 7.47 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -48.73% |
| Mar 31, 2026 | 75.22% |
| Dec 31, 2025 | -357.10% |
| Sep 30, 2025 | -42.40% |
| Jun 30, 2025 | -77.83% |
| Mar 31, 2025 | 83.03% |
| Dec 31, 2024 | -50.91% |
| Sep 30, 2024 | 49.96% |
| Jun 30, 2024 | -142.62% |
| Mar 31, 2024 | 18.52% |
| Dec 31, 2023 | -21.39% |
| Sep 30, 2023 | 78.43% |
| Jun 30, 2023 | 41.33% |
| Mar 31, 2023 | -903.06% |
| Dec 31, 2022 | -67.77% |
| Sep 30, 2022 | 73.10% |
| Jun 30, 2022 | -231.97% |
| Mar 31, 2022 | 63.73% |
| Dec 31, 2021 | -103.49% |
| Sep 30, 2021 | 53.55% |